Futura Medical Share Discussion Threads

[supernumerary] 16/4/2019 18:36

Mira - LO have been reducing for ages - check the holdings RNSs - and it looks as though they want out. I doubt the random magazine article means much in the grand scheme of things. However, given LO's current holding, there's the prospect of a lot more pain still to come for other holders. Caveat emptor.

[akmal101] 16/4/2019 17:20

After hours rns?

[cf456] 15/4/2019 11:43

hTTps://www.investorschronicle.co.uk/comment/2019/04/15/futura-s-blue-sky-opportunity/

[j777j] 15/4/2019 11:43

This is just waiting to be snapped up by a larger fish.

[mirabeau] 15/4/2019 11:24

Tipped by ST in the IC

[j777j] 12/4/2019 13:19

Yes very impressive.

[martinelwick] 12/4/2019 08:15

I have just listened to the Investor presentation.I have to say that you cannot help but be impressed by Ken James.He is enthusiastic about the product,and about the progress of the studies ,but more importantly ,he explains everything with great clarity.Despite all the past wrong turns,I strongly feel if Med is only half as effective as FUM hope it is still going to be a massive driver of share holder value.If only Lombard were not sitting on millions of shares that will feed the market I'm sure we would see real progress in the share price.Keep the faith.

[herb clark] 12/4/2019 07:50

Why the rise?

[andyj] 12/4/2019 07:46

Bouncing back strongly!

[rrr] 11/4/2019 15:10

Interesting webcast. Recruitment going well. Headline data expected by year end, maybe sooner. Let's hope that the rules are being followed properly at each centre, if that's ok it's looking good for MED I think.

[groogis] 11/4/2019 13:57

Puntastic post. Deserved more people pushing their thumbs up....

[j777j] 11/4/2019 13:40

htTPS://webcasting.brrmedia.co.uk/broadcast/5ca77b48eb566331974d52e8

[j777j] 11/4/2019 13:37

Good webcast.I like Ken James he is more able to speak in words the masses can understand.Clearly the co know what they have been offered by potential partners,yet believe they can get significantly more by hanging on until year end.We know Singer has pencilled in $30 million in upfront and milestone payments from Europe and $60 million from the USA.Phase 3 is all systems go with 500 recruits already expected to have been enrolled by end of this week.Not long to wait.

[slicethepie] 11/4/2019 07:44

Barder is out of his depth, there is some fantastic science here but it needs someone with vision/ contacts to exploit it. He has been here too long!

[creditcrunchies] 10/4/2019 22:42

what happened with the Blue Diamond condoms? They were in sale in Holland and Belgium now they've completely disappeared. The feedback on these from what I've seen was pretty positive from people that bought them then nothing. Was it Durex pulling out that finished this product range off? All I can think is Durex pulled out to develop their own product but I cannot see one out there anything like this they've focused on different gel types to delay the inevitable not the make it rock hard.

[supernumerary] 10/4/2019 17:05

mtb - I find it pretty unbelievable that nobody's prepared to take this to market. Seems like a perfect product for some upstart newcomer to take on. I wonder what terms Barder's asking for? He really is a lazy sod, isn't he?

[mikethebike4] 10/4/2019 15:57

tiananmen that is exactly what FUM said about CSD500 the 'viagra' condom and look what happened to that - nothing, except revenue down from £360K in 2017 to ZERO in 2018 ! - at least in 2017 it covered Barders 1/4million+ remuneration ! From todays report :- CSD500 - condom containing the erectogenic Zanifil(R) gel In September 2018, Futura received approval for a two-year shelf life for CSD500 for its European contract condom manufacturer. This milestone provides the company with an opportunity to focus its R&D resource fully on the far greater potential of its leading asset, MED2005. As an innovative specialist R&D company, Futura does not have the marketing or regulatory medical device resource available to support the day-to-day requirements in a growing compliance-driven market and is in discussions with potential partners to assume these obligations. Futura expects to still benefit from the Intellectual Property of CSD500 through potential royalties, but the immediate potential for substantial royalties is low in the absence of a large global brand 'carrier' to take the product forward as previously advised. The Company will continue to explore national, multi-territory and regional agreements where the opportunities arise. The Company is expected to benefit from annual cost savings of approximately GBP400k in the event that it no longer maintains regulatory clearance itself for CSD500 as a medical device. - don't hold your breath !

[tiananmen] 10/4/2019 14:38

We were not expecting anything significant from today's announcement and that is what we got. We still have to wait until the Phase III results are finished until it gets approval, nothing has changed, the early signs is that this drug is going to make a substantial impact on the market.

[j777j] 10/4/2019 12:57

That is for the USAFirst one is for Europe and we are half way stage.15% royalties on $1.4 billion peak sales is $210,000,000 a year.That is 5 times current market cap annually.All to play for.

[5oletrader] 10/4/2019 12:30

They also said... "Planning for a SECOND, CONFIRMATORY Phase 3 study for MED2005 has been UNDERTAKEN.. ... THIS STUDY is expected to be informed by the FIRST Phase 3 and therefore START AFTER END of the FIRST PHASE 3 STUDY... The way I see it - 'POTENTIAL' and 'EXECUTION' are two totally different beasts. Only time will tell. ATB

[j777j] 10/4/2019 11:26

Meanwhile back in the real world,it is all systems go for a product that could generate 15% royalties on peak sales of $1.4 billion pa."Futura medical confirmed it will deliver the results from its phase III trial for a fast-acting gel for erectile dysfunction (ED) by the end of the year, a milestone which expects to be a "major value inflection point". The first of two studies of MED2005 got underway in October treating 1,000 men at 60 centres across Europe. Headline data should be released towards the back-end of 2019, the company said."

[slicethepie] 10/4/2019 09:28

It's incompetence, barder background is insurance, he has no experience exploiting technology, if the board was credible it would have replaced him but they are his appointees.

[lbo] 10/4/2019 09:26

Futura Medical plc James Barder, Chief Executive mail to: [e-mail]